Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on Guardian Pharmacy (GRDN) to $38 from $35 and keeps an Outperform rating on the shares following quarterly results. The firm says the Q4 beat was partially due to non-continuing factors but also several sustainable drivers. Overall, Oppenheimer believes Guardian remains well positioned for growth, driven by an attractive position in a market poised for growth due to the silver tsumani.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN:
- Guardian Pharmacy price target raised to $38 from $34 at Truist
- Guardian Pharmacy Services Posts Strong Growth Amid Headwinds
- Guardian Pharmacy reports Q4 EPS 37c, consensus 27c
- Guardian Pharmacy backs FY26 revenue view of $1.40B-$1.42B, consensus $1.42B
- GRDN Upcoming Earnings Report: What to Expect?